25 results on '"Hirsch, Michelle S"'
Search Results
2. Fumarate hydratase-deficient renal cell carcinoma: The real-world experience at Dana-Farber Cancer Institute and Moores Cancer Center.
3. Distinct oncogenic signatures in malignant PEComa and leiomyosarcoma identified by integrative RNA-seq and H3K27ac ChIP-seq analysis.
4. TSC1-mutant bladder cancer expression signature in relation to nuclear localization of TFE3 and potential for targetable dependency.
5. Single cell transcriptomic characterization of natural killer (NK) cell populations in clear cell renal cell carcinoma and association with clinical outcomes.
6. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
7. Genomic profiling of variant urinary tract tumor histologies.
8. Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.
9. Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).
10. Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC).
11. Tumor genomic mutation profiling of germ cell tumors using “Profile”.
12. PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
13. Smoking history and disease outcomes in patients with malignant germ cell tumors.
14. Clinicopathologic features and clinical outcomes associated with Gleason upgrading from biopsy to radical prostatectomy.
15. Detecting lower in addition to the highest Gleason score prostate cancer on core biopsy and the odds of upgrading at radical prostatectomy.
16. Multidisciplinary care and management of very low-risk prostate cancer.
17. A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.
18. A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy.
19. Multidisciplinary Care and Pursuit of Active Surveillance in Low-Risk Prostate Cancer
20. Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis
21. PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target?
22. Genetic polymorphisms’ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents.
23. Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition.
24. KRAS and EGFR mutations to distinguish adenocarcinomas and squamous cell carcinomas of the cervix.
25. Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.